Twist Bioscience Corporation (TWST) drops on deep earnings beat
Twist Bioscience Corporation (TWST) beat earnings and revenue estimates, yet the stock drops as investors weigh valuation, margin progress and growth expectations. This deep-dive examines the company’s 15th straight quarter of sequential revenue growth, AI drug discovery momentum, NGS expansion and the path toward sustained profitability.
Twist Bioscience (TWST) delivered a deep earnings beat in fiscal 2026 fourth quarter, with a smaller-than-expected loss and revenue above estimates, yet the stock fell 7.61% as investors focused on valuation and execution risk. The company posted 28% revenue growth, positive adjusted EBITDA, and strong AI drug discovery momentum, signaling improving fundamentals even as it remains unprofitable on a GAAP basis.
Twist Bioscience Corporation (TWST) drops after earnings
Twist Bioscience Corporation (TWST) beat both earnings and revenue estimates in fiscal 2026’s fourth quarter, with a $0.32 per-share loss versus the expected $0.38707 loss and revenue of $126.6 million versus an estimated $0.12 billion. Still, TWST drops 7.61% to $113.26 in the Nov. 12, 2026 regular session. The decline shows that a clean quarterly beat does not automatically satisfy a stock priced around ambitious growth expectations.
Key Takeaways
TWST earnings beat estimates on both lines. The company reported a $0.32 EPS loss against an estimated $0.38707 loss and $126.6 million in revenue against an estimated $0.12 billion.
Revenue grew 28% year over year, marking Twist Bioscience’s 15th consecutive quarter of sequential growth.
AI drug discovery was the standout growth engine. Fiscal 2026 revenue reached $59.1 million, up 175% from $21.5 million in fiscal 2025, while orders more than doubled.
NGS revenue grew 24% year over year and 6% sequentially in the fourth quarter, supported by diagnostic customers and the launch of MRD Express.
CEO Emily Leproust said AI drug discovery should remain one of the company’s fastest-growing product groups in fiscal 2027, with order momentum accelerating through the year.
Analyst sentiment remains constructive but divided. The recorded consensus shows 11 buys, 2 holds and 2 sells, while recent target increases included $190 from TD Cowen, $205 from Canaccord Genuity, $215 from Barclays and $212 from Guggenheim.
Financial Performance: Growth, Margins and the Path to Profitability
The core TWST earnings result was straightforward. Fourth-quarter revenue reached $126.6 million, beating the estimated $0.12 billion and rising 28% from the prior year. The result also extended a long operating trend. Management reported 15 straight quarters of sequential revenue growth, giving Twist a record of consistent expansion rather than a single strong period.
The quarterly revenue path has moved from $0.10 billion in September 2025 to $0.10 billion in December, $0.11 billion in March, $0.12 billion in June and $0.13 billion in September 2026. Full-year revenue reached almost $460 million, up 22% and more than $30 million above the company’s initial fiscal 2026 guidance.
“This is our 15th consecutive quarter of sequential growth.” - Emily Leproust, CEO and Co-Founder, Earnings Call
The earnings trend also improved. The $0.32 per-share loss was narrower than the $0.56 loss in the June quarter, the $0.71 loss in March and the $0.50 loss in December. It also improved on the $0.45 loss recorded in the year-ago quarter. The result beat the consensus estimate, although Twist remained loss-making on a per-share basis.
Profitability delivered the quarter’s most important operational milestone. Adjusted EBITDA turned positive at $2.2 million, while full-year gross margin reached 52.4%. The company also reported fourth-quarter net income of -$0.02 billion, an improvement from -$0.04 billion in each of the March and June quarters.
“Fiscal 2026 was a pivotal year for Twist.” - Emily Leproust, CEO and Co-Founder, Earnings Call
Segment performance explains why the growth story still attracts attention. AI drug discovery revenue increased from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026. Orders more than doubled, and management described repeat customer activity across pilot orders, model-building work and recurring drug discovery cycles.
The NGS business also produced a solid fourth quarter. Revenue rose 24% year over year and 6% sequentially, driven by diagnostic customers. Twist launched MRD Express two weeks before the results, adding a commercial product aimed at molecular residual disease testing. The company also introduced whole-genome sequencing library preparation solutions for rare disease and population genetics applications.
Twist raised approximately $425 million in net proceeds through an equity offering and at-the-market sales. Management plans to direct that capital toward AI drug discovery characterization, MRD capacity and other growth opportunities. The financing gives Twist more room to invest, but it also places greater weight on whether those investments produce enough revenue to offset the cost of expansion.
“We intend to reinvest our profits in the capabilities, capacity and people that can drive top line growth moving forward.” - Emily Leproust, CEO and Co-Founder, Earnings Call
The strategic narrative is built around capacity. Twist increased protein and antibody manufacturing capacity by almost 200% over the past 12 months and expanded characterization capabilities by 2 to 5 times, depending on the assay. Management also described another 5-times characterization capacity expansion from the fiscal 2026 exit level. Those investments support the company’s stated plan to build ahead of demand.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
TWST’s market reaction was negative despite the earnings beat. At 14:30 ET on Nov. 12, shares traded at $113.26, down 7.61%. Trading volume reached 3,912,100 shares versus an average of 2,367,237 shares. The move suggests that investors demanded more than a narrower loss and strong revenue growth from a company with a $7.5 billion market capitalization.
The reaction also reflects the gap between operating progress and valuation expectations. Twist delivered positive adjusted EBITDA, rapid AI drug discovery growth and a 15-quarter streak of sequential revenue gains. Yet the stock still sold off, showing that market psychology can punish a growth company when the quarter does not reset expectations high enough.
Analyst positioning before the results leaned bullish. The current consensus includes 11 buy ratings, 2 holds and 2 sells. Jefferies initiated coverage with a Hold rating and a $150 price target on Oct. 8, adding a more cautious view to an otherwise positive group.
Several firms raised targets in October. TD Cowen increased its target from $115 to $190 on Oct. 13. Canaccord Genuity moved from $120 to $205 on Oct. 12. Barclays raised its target from $112 to $215 on Oct. 7, while Guggenheim moved from $107 to $212 on Oct. 1. These targets show how strongly some analysts value Twist’s AI drug discovery and synthetic biology opportunity.
The contrast between those bullish targets and the immediate share-price drop is important. Analysts have rewarded Twist for revenue growth, new products and improving margins, while the market reaction shows that execution must keep pace with the stock’s growth narrative. In practical terms, the company has earned credibility on growth, but investors still want proof that capacity investments will produce durable earnings power.
“AI Drug Discovery delivered an exceptional year.” - Emily Leproust, CEO and Co-Founder, Earnings Call
Bottom Line
Twist Bioscience Corporation earnings showed real operating progress: revenue beat estimates, AI drug discovery expanded sharply and adjusted EBITDA turned positive. However, TWST drops after the results because investors are pricing a demanding growth story, so future returns depend on converting new capacity, AI demand and NGS products into sustained profitability.
+Why did Twist Bioscience stock fall after beating earnings?
Twist Bioscience beat both EPS and revenue estimates, but shares still dropped 7.61% to $113.26 because investors appeared to expect even stronger results and clearer proof of sustained profitability. The market reaction suggests the stock was priced for ambitious growth, so a clean beat was not enough to drive the shares higher.
+How did Twist Bioscience perform in fiscal 2026 fourth quarter?
Twist reported a $0.32 per-share loss versus the expected $0.38707 loss and revenue of $126.6 million versus an estimated $120 million. Revenue rose 28% year over year, marking the company’s 15th consecutive quarter of sequential revenue growth.
+What was the biggest growth driver for TWST in fiscal 2026?
AI drug discovery was the standout growth engine, with fiscal 2026 revenue rising to $59.1 million from $21.5 million in fiscal 2025. Orders more than doubled, and management said repeat customer activity is increasing across pilot orders, model-building work and recurring drug discovery cycles.
+Is Twist Bioscience becoming profitable?
Twist is not yet profitable on a GAAP basis, but it made progress toward profitability in the quarter. The company posted positive adjusted EBITDA of $2.2 million and full-year gross margin of 52.4%, showing improving operating leverage even though it still reported a per-share loss.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on TWST?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
